Refractive surgery techniques could raise IOP and lead to glaucoma

Article

The risk of glaucoma after refractive surgery procedures should not be underestimated, claims José Belda, MD, speaking at the Alicante Refractiva International meeting, held March 6–8 in Spain.

The risk of glaucoma after refractive surgery procedures should not be underestimated, claims José Belda, MD, speaking at the Alicante Refractiva International meeting, held March 6–8 in Spain.

Dr Belda, of Vissum Institute in Alicante, said that, as the volume of refractive surgery is constantly increasing, and that the largest part of refractive surgery procedures are performed in myopic patients, amongst whom the prevalence of glaucoma is three- to four-times higher than normal, there may be a large quantity of patients presenting this problem in the future.

True intraocular pressure (IOP) levels are difficult to assess after surgery, regardless of the technique used: this can lead to IOP being underestimated, which results in glaucoma going undiagnosed for a long time. Each technique, however, can have additional problems of its own. For example, the high levels of corticosteroids used with surface techniques may lead to corticosteroid-induced glaucoma, particularly in patients with high myopia, while the pressure values during the vacuum phase of LASIK procedures can reach as high as 200 mmHg. Furthermore, the extra length of a femtosecond procedure can cause damage to the optic nerve because of the longer time that the cornea is flattened. It has not yet been proved whether this pressure increase is safe in eyes with underlying glaucoma or ocular hypertension.

Dr Belda concluded by saying that he believed that most cases of glaucoma after refractive surgery are related to corticosteroid-induced increases in IOP.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.